Rivarelta 10mg Herabiopharm medicine prevents venous thrombosis (3 blisters x 10 tablets)

pharmacokinetics

No data.

After conducting hip joint surgery, the recommended treatment time is 5 weeks.

After conducting knee surgery, the recommendation for treatment for 2 weeks.

Prevention of stroke and body embolism:

In patients with high risk of relapse DVT or PE, such as complicated pathology, or people with DVT or PE recurrence when expanding with Rivaroxaban 10 mg x 1 time/day, should consider with the dose of Rivaroxaban 20 mg 1 time/day.

Unnecessary dose adjustment for patients with mild renal function (creatinine clearance coefficient 50 - 80 ml/min).

Liver functional impairment: Rivaroxaban is contraindicated in patients with liver disease with blood clotting and clinical bleeding, including patients with cirrhosis group B and C according to Child Pugh classification.

Elderly: No dose adjustment.

Children and teenagers:

Safety and effectiveness of Rivaroxaban in children from 0 to 18 years old has not been set up, no available data. Therefore, it is not recommended to use Rivaroxaban for children under 18 years old.

Patients with atrial fibrillation due to the disease of the heart valve intervention through the skin (PCI) along with the stent:

Experience in reducing the dose of rivaroxaban 15 mg/time/day (or 10 mg/day/day for patients with medium renal function (Creatinine clearance coefficient of 30 - 49 ml/min)) in combination with a P2Y12 inhibitor for up to 12 months in patients with atrial fibrillation due to anticoagulant medication and coronary artery intervention (PCI), which is still limited to stent.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when using overdose?

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Be cautious when using

recommendations for clinical monitoring in accordance with anti -coagulation practice during treatment.

Like other anticoagulants, patients using Rivarelta must be carefully observed with signs of bleeding. Recommendations should be used carefully in diseases that increase the risk of bleeding. Rivarelta must be stopped if serious bleeding occurs.

Rivaroxaban should be used cautiously in patients with creatinine clearance 15 - 29 ml/min. Do not use rivaroxaban for patients with creatinine clearance ratio

As other anti -thrombotic drugs, Rivaroxaban is not used in patients at risk of increased bleeding.

If an invasive or surgical intervention is required, it is necessary to stop Rivaroxaban immediately for at least 24 hours before intervention if possible and based on the clinical assessment of the doctor.

The older the person, the risk of bleeding increases.

This product contains lactose. Patients with rare genetic problems are galactose intolerance, lactase deficiency or poor absorbing glucose-galactose should not take this drug.

Women during pregnancy and lactation

Pregnant women:

Due to reproductive toxicity, the risk of bleeding and evidence shows that Rivaroxaban passes the placenta, does not use Rivaroxaban for pregnant women.

Women should avoid pregnancy during treatment with Rivaroxaban.

breastfeeding women:

Contraindicated using Rivaroxaban in breastfeeding women.

The ability to drive and operate machinery

The adverse reactions such as temporary and dizziness (common) are recorded.

Patients who have these unwanted effects should not drive or use machines.

Drug interaction

CYP3A4 and P-GP inhibitors: It is not recommended to use Rivaroxaban simultaneously with antifungal drugs Azole in the body or HIV Protease inhibitors.

Anticoagulant drugs: Increasing the risk of bleeding, careful monitoring of patients who use Rivaroxaban simultaneously with other anticoagulants.

NSAIDs or platelets inhibitors: It is important to pay attention to patients using simultaneously with NSAIDs and platelet aggregation inhibitors because these substances increase the risk of bleeding.

CYP3A4 enzyme induction drugs: simultaneous use of Rivaroxaban with strong CYP3A4 induction substances can also lead to reduced plasma concentrations of rivaroxaban.